In-vitro activity of plazomicin, meropenem-vaborbactam, and omadacycline against carbapenem-resistant Gram-negative isolates in Egypt

References

• Petca RC, Negoiță S, Mareș C, et al. Heterogeneity of antibiotics Multidrug-Resistance profile of uropathogens in Romanian population. Antibiotics. 2021;10(5):523.
   Google Scholar
• Bassetti M, Peghin M, Vena A, et al. Treatment of infections due to MDR gram-negative bacteria. Front Med (Lausanne). 2019;6:74–83.
   PubMed Web of Science ®Google Scholar
• Garoy EY, Gebreab YB, Achila OO, et al. Magnitude of multidrug resistance among bacterial isolates from surgical site infections in two national referral hospitals in Asmara, Eritrea. Int J Microbiol. 2021;2021:6690211–6690222.
   Web of Science ®Google Scholar
• McCann E, Srinivasan A, DeRyke CA, et al. Carbapenem-nonsusceptible gram-negative pathogens in ICU and non-ICU settings in US hospitals in 2017: a multicenter study. Open Forum Infect Dis. 2018;5(10):241–247.
   Web of Science ®Google Scholar
• Kotb S, Lyman M, Ismail G, et al. Epidemiology of carbapenem-resistant enterobacterales in egyptian intensive care units using national healthcare–associated infections surveillance data, 2011–2017. Antimicrob Resist Infect Control. 2020;9(1):1–9.
   PubMed Web of Science ®Google Scholar
• Morris S, Cerceo E. Trends, epidemiology, and management of multi-drug resistant gram-negative bacterial infections in the hospitalized setting. Antibiotics. 2020;9(4):196–215.
   Google Scholar
• Codjoe FS, Donkor ES. Carbapenem resistance: a review. J Med Sci. 2018;6(1):1–28. ‏
   Google Scholar
• Chamieh A, El-Hajj G, Zmerli O, et al. Carbapenem resistant organisms: a 9-year surveillance and trends at Saint George university medical center. J Infect Public Health. 2020;13(12):2101–2106.
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and Prevention (CDC). Antibiotic resistance threats in the United States, 2019. Atlanta, GA: U.S. Department of Health and Human Services, CDC; 2019; p. 16.
   Google Scholar
• Abdelaziz NA. Phenotype-genotype correlations among carbapenem-resistant enterobacterales recovered from four Egyptian hospitals with the report of SPM carbapenemase. Antimicrob Resist Infect Control. 2022;11(1):1–10.
   PubMed Web of Science ®Google Scholar
• Petty LA, Henig O, Patel TS, et al. Overview of meropenem-vaborbactam and newer antimicrobial agents for the treatment of carbapenem-resistant enterobacterales. Infect Drug Resist. 2018;11:1461–1472.
   PubMed Web of Science ®Google Scholar
• León-Buitimea A, Garza-Cárdenas CR, Garza-Cervantes JA, et al. The demand for new antibiotics: antimicrobial peptides, nanoparticles, and combinatorial therapies as future strategies in antibacterial agent design. Front Microbiol. 2020;11:1669–1678.
   PubMed Web of Science ®Google Scholar
• Eljaaly K, Alharbi A, Alshehri S, et al. Plazomicin: a novel aminoglycoside for the treatment of resistant gram-negative bacterial infections. Drugs. 2019;79(3):243–269.
   PubMed Web of Science ®Google Scholar
• Terreni M, Taccani M, Pregnolato M. New antibiotics for multidrug-resistant bacterial strains: latest research developments and future perspectives. Molecules. 2021;26(9):2671–2701.
   PubMed Web of Science ®Google Scholar
• Baker DE. Omadacycline. Hosp Pharm. 2019;54(2):80–87.
   PubMed Web of Science ®Google Scholar
• Novelli A, Del Giacomo P, Rossolini GM, et al. Meropenem/vaborbactam: a next generation β-lactam β-lactamase inhibitor combination. Expert Rev Anti Infect Ther. 2020;18(7):643–655.
   PubMed Web of Science ®Google Scholar
• Clinical and Laboratory Standards Institute (CLSI). Performance standards for antimicrobial susceptibility testing. In: 30th CLSI Supplement M100. Performance Standards for Antimicrobial Susceptibility Testing: 30th Informational Supplement. Wayne: Clinical and Laboratory Standards Institute; 2020.
   Google Scholar
• Amjad A, Mirza I, Abbasi S, et al. Modified hodge test: a simple and effective test for detection of carbapenemase production. Iran J Microbiol. 2011;3(4):189–193.
   PubMedGoogle Scholar
• Abouelfetouh A, Torky AS, Aboulmagd E. Phenotypic and genotypic characterization of carbapenem-resistant Acinetobacter baumannii isolates from Egypt. Antimicrob Resist Infect Control. 2019;8(1):1–9.
   PubMed Web of Science ®Google Scholar
• Jing X, Zhou H, Min X, et al. The simplified carbapenem inactivation method (sCIM) for simple and accurate detection of carbapenemase-producing gram-negative bacilli. Front Microbiol. 2018;9:2391–2398.
   PubMed Web of Science ®Google Scholar
• US Food and Drug Administration. FDA-identified interpretive criteria. 2019. Available from: https://www.fda.gov/drugs/development-resources/plazomicin-injection.
   Google Scholar
• Pfaller MA, Huband MD, Shortridge D, et al. Surveillance of omadacycline activity tested against clinical isolates from the United States and Europe: report from the SENTRY antimicrobial surveillance program, 2016 to 2018. Antimicrob Agents Chemother. 2020;64(5):e02488–19.
   PubMed Web of Science ®Google Scholar
• Kahlmeter, Gunnar, et al. “Point-counterpoint: differences between the European Committee on Antimicrobial Susceptibility Testing and Clinical and Laboratory Standards Institute recommendations for reporting antimicrobial susceptibility results- Breakpoint tables for interpretation of MICs and zone diameters, version 9.0.” Journal of clinical microbiology 2019;57(9):e01129–19.
   Google Scholar
• Jean S, Garrett S, Anglade C, et al. Multicenter clinical evaluation of E test meropenem-vaborbactam (bioMérieux) for susceptibility testing of enterobacterales (enterobacterales) and Pseudomonas aeruginosa. J Clin Microbiol. 2019;58(1):e01205–e01219.
   PubMed Web of Science ®Google Scholar
• Shebl RI, Mosaad YO. Frequency and antimicrobial resistance pattern among bacterial clinical isolates recovered from different specimens in Egypt. Cent African J Public Heal. 2019;5(1):36–45.
   Google Scholar
• Fahim NA. Prevalence and antimicrobial susceptibility profile of multidrug-resistant bacteria among intensive care units patients at ain shams university hospitals in Egypt—a retrospective study. J Egypt Public Health Association. 2021;96(1):1–10.
   PubMed Web of Science ®Google Scholar
• Tan R, Liu J, Li M, et al. Epidemiology and antimicrobial resistance among commonly encountered bacteria associated with infections and colonization in intensive care units in a university-affiliated hospital in shanghai. J Microbial Immunol Infect. 2014;47(2):87–94.
   Web of Science ®Google Scholar
• Alexopoulou A, Papadopoulos N, Eliopoulos DG, et al. Increasing frequency of gram‐positive cocci and gram‐negative multidrug‐resistant bacteria in spontaneous bacterial peritonitis. Liver Int. 2013;33(7):975–981.
   PubMed Web of Science ®Google Scholar
• Bandy A, Tantry B. ESBL activity, MDR, and carbapenem resistance among predominant enterobacterales isolated in 2019. Antibiotics. 2021;10(6):744–755.
   Google Scholar
• Makanjuola OB, Fayemiwo SA, Okesola AO, et al. Pattern of multidrug resistant bacteria associated with intensive care unit infections in Ibadan, Nigeria. Ann Ibadan Postgrad Med. 2018;16(2):162–169.
   PubMedGoogle Scholar
• Alkofide H, Alhammad AM, Alruwaili A, et al. Multidrug-Resistant and extensively Drug-Resistant enterobacterales: Prevalence, treatments, and outcomes–a retrospective cohort study. Infect Drug Resist. 2020;13:4653–4662.
   PubMed Web of Science ®Google Scholar
• Okoche D, Asiimwe BB, Katabazi FA, et al. Prevalence and characterization of carbapenem-resistant enterobacteriaceae isolated from mulago national referral. PloS One. 2015;48:1–11.
   Google Scholar
• Mushi MF, Mshana SE, Imirzalioglu C, et al. Carbapenemase genes among multidrug resistant gram negative clinical isolates from a tertiary hospital in Mwanza, Tanzania. Biomed Res Int. 2014;2014:303104–303108.
   PubMed Web of Science ®Google Scholar
• Martins AF, Bail L, Ito CA, et al. Antimicrobial activity of plazomicin against enterobacterales-producing carbapenemases from 50 Brazilian medical centers. Diagn Microbiol Infect Dis. 2018;90(3):228–232.
   PubMed Web of Science ®Google Scholar
• Castanheira M, Davis AP, Mendes RE, et al. In- vitro activity of plazomicin against gram-negative and gram-positive isolates collected from US hospitals and comparative activities of aminoglycosides against carbapenem-resistant enterobacterales and isolates carrying carbapenemase genes. Antimicrob Agents Chemother. 2018;62(8):e00313–00318.
   PubMed Web of Science ®Google Scholar
• Castanheira M, Sader HS, Mendes RE, et al. Activity of plazomicin tested against enterobacterales isolates collected from U.S. hospitals in 2016–2017: Effect of different breakpoint criteria on susceptibility rates among aminoglycosides. Antimicrob Agents Chemother. 2020;64(5):e02418–02419.
   PubMed Web of Science ®Google Scholar
• Landman D, Kelly P, Bäcker M, et al. Antimicrobial activity of a novel aminoglycoside, ACHN-490, against Acinetobacter baumannii and Pseudomonas aeruginosa from New York city. J Antimicrob Chemother. 2011;66(2):332–334.
   PubMed Web of Science ®Google Scholar
• Biedenbach DJ, Jones RN, Armstrong ES, et al. Activity of ACHN-490 against complicated urinary tract infection (cUTI) pathogens from the United States and Europe. In: Poster Presented at 49^th Interscience Conference on Antimicrobial Agents and Chemotherapy; 2009 Sep 12–15; San Francisco, CA.
   Google Scholar
• Jones RN, Armstrong ES, Aggen JB, et al. Antimicrobial activity of ACHN-490, a neoglycoside, tested against a contemporary collection of clinical isolates including problematic antimicrobial-resistant phenotypes. In: Poster Presented at 49^th Interscience Conference on Antimicrobial Agents and Chemotherapy; 2009 Sep 12–15, San Francisco, CA.
   Google Scholar
• Landman D, Babu E, Shah N, et al. Activity of a novel aminoglycoside, ACHN-490, against clinical isolates of Escherichia coli and Klebsiella pneumoniae from New York city. J Antimicrob Chemother. 2010;65(10):2123–2127.
   PubMed Web of Science ®Google Scholar
• Zhanel GG, Lawson CD, Zelenitsky S, et al. Comparison of the next-generation aminoglycoside plazomicin to gentamicin, tobramycin and amikacin. Expert Rev Anti Infect Ther. 2012;10(4):459–473.
   PubMed Web of Science ®Google Scholar
• Walkty A, Adam H, Baxter M, et al. In vitro activity of plazomicin against 5,015 gram-negative and gram-positive clinical isolates obtained from patients in Canadian hospitals as part of the CANWARD study, 2011-2012. Antimicrob Agents Chemother. 2014;58(5):2554–2563.
   PubMed Web of Science ®Google Scholar
• Castanheira M, Streit JM, Deshpande LM, et al. Activity of plazomicin and comparator agents tested against recent clinical isolates collected in asia–pacific, Europe, and Latin America. In: Poster Presented at 27^th European Congress of Clinical Microbiology and Infectious Diseases, 2017 Apr 22–25, Vienna.
   Google Scholar
• Badal R, Lob S, Hackel M, et al. In vitro activity of ACHN-490 against recent respiratory tract pathogens. In: Poster Presented at 51^st Interscience Conference on Antimicrobial Agents and Chemotherapy; 2011, Chicago, IL, p. 17–20.
   Google Scholar
• Zhanel GG, Adam HJ, Baxter M, et al. In vitro activity of plazomicin against gram-negative and gram-positive pathogens isolated from patients in Canadian hospitals in 2011–2015: CANWARD surveillance study. In: Poster Presented at 2^nd American Society for Microbiology Microbe, 2017 Jun 1–5, New Orleans.
   Google Scholar
• Castanheira M, Doyle TB, Kantro V, et al. Meropenem-vaborbactam activity against carbapenem-resistant enterobacterales isolates collected in US hospitals during 2016 to 2018. Antimicrob Agents Chemother. 2020;64(2):e01951–19.
   PubMed Web of Science ®Google Scholar
• Livermore DM, Mushtaq S, Warner M, et al. Activity of aminoglycosides, including ACHN-490, against carbapenem-resistant enterobacterales isolates. J Antimicrob Chemother. 2011;66(1):48–53.
   PubMed Web of Science ®Google Scholar
• Thaden JT, Pogue JM, Kaye KS. Role of newer and re-emerging older agents in the treatment of infections caused by carbapenem-resistant enterobacterales. Virulence. 2017;8(4):403–416.
   PubMed Web of Science ®Google Scholar
• Sheu CC, Chang YT, Lin SY, et al. Infections caused by carbapenem-resistant enterobacterales: an update on therapeutic options. Front Microbiol. 2019;10:80–92.
   PubMed Web of Science ®Google Scholar
• Pfaller MA, Huband MD, Mendes RE, et al. In vitro activity of meropenem/vaborbactam and characterisation of carbapenem resistance mechanisms among carbapenem-resistant enterobacterales from the 2015 meropenem/vaborbactam surveillance programme. Int J Antimicrob Agents. 2018;52(2):144–150.
   PubMed Web of Science ®Google Scholar
• Castanheira M, Huband MD, Mendes RE, et al. Meropenem-vaborbactam tested against contemporary gram-negative isolates collected worldwide during 2014, including carbapenem-resistant, KPC-producing, multidrug-resistant, and extensively drug-resistant enterobacterales. Antimicrob Agents Chemother. 2017;61(9):e00567–17.
   PubMed Web of Science ®Google Scholar
• Castanheira M, Rhomberg PR, Flamm RK, et al. Effect of the β-lactamase inhibitor vaborbactam combined with meropenem against serine carbapenemase-producing enterobacteriaceae. Antimicrob Agents Chemother. 2016;60(9):5454–5458.
   PubMed Web of Science ®Google Scholar
• Shortridge D, Carvalhaes C, Deshpande L, et al. Activity of meropenem/vaborbactam and comparators against gram-negative isolates from Eastern and Western european patients hospitalized with pneumonia including ventilator-associated pneumonia (2014–19). J Antimicrob Chemother. 2021;76(10):2600–2605.
   PubMed Web of Science ®Google Scholar
• Johnston BD, Thuras P, Porter SB, et al. Activity of meropenem/vaborbactam against international carbapenem-resistant Escherichia coli isolates in relation to clonal background, resistance genes, resistance to comparators and region. J Glob Antimicrob Resist. 2021;24:190–197.
   PubMed Web of Science ®Google Scholar
• Pfaller MA, Huband MD, Shortridge D, et al. Surveillance of omadacycline activity tested against clinical isolates from the United States and Europe as part of the 2016 SENTRY antimicrobial surveillance program. Antimicrob Agents Chemother. 2018;62(4):1–7.
   Web of Science ®Google Scholar
• Xiao M, Huang JJ, Zhang G, et al. Antimicrobial activity of omadacycline in vitro against bacteria isolated from 2014 to 2017 in China, a multi-center study. BMC Microbiol. 2020;20(1):1–9.
   PubMed Web of Science ®Google Scholar
• Dong D, Zheng Y, Chen Q, et al. In vitro activity of omadacycline against pathogens isolated from mainland China during 2017–2018. Eur J Clin Microbiol Infect Dis. 2020;39(8):1559–1572.
   PubMed Web of Science ®Google Scholar
• Tanaka SK, Steenbergen J, Villano S. Discovery, pharmacology, and clinical profile of omadacycline, a novel aminomethylcycline antibiotic. Bioorg Med Chem. 2016;24(24):6409–6019.
   PubMed Web of Science ®Google Scholar
• Huband MD, Pfaller MA, Shortridge D, et al. Surveillance of omadacycline activity tested against clinical isolates from the United States and Europe: results from the SENTRY antimicrobial surveillance programme, 2017. J Glob Antimicrob Resist. 2019;19:56–63.
   PubMed Web of Science ®Google Scholar
• Carvalhaes CG, Huband MD, Reinhart HH, et al. Antimicrobial activity of omadacycline tested against clinical bacterial isolates from hospitals in mainland China, Hong Kong, and Taiwan: results from the SENTRY antimicrobial surveillance program (2013 to 2016). Antimicrob Agents Chemother. 2019;63(3):e02262–18.
   PubMed Web of Science ®Google Scholar
• Iregui A, Landman D, Quale J. Activity of omadacycline and other tetracyclines against contemporary Gram-Negative pathogens from New York city hospitals. Microb Drug Resist. 2021;27(2):190–195.
   PubMed Web of Science ®Google Scholar
• Cunrath O, Meinel DM, Maturana P, et al. Quantitative contribution of efflux to multi-drug resistance of clinical Escherichia coli and Pseudomonas aeruginosa strains. EBioMedicine. 2019;41:479–487.
   PubMed Web of Science ®Google Scholar
• Khalili H, Soltani R, Negahban S, et al. Reliability of disk diffusion test results for the antimicrobial susceptibility testing of nosocomial gram-positive microorganisms: is E-test method better? Iran J Pharm Res. 2012;11(2):559–563.
   PubMed Web of Science ®Google Scholar
• Castanheira M, Deshpande LM, Woosley LN, et al. Activity of plazomicin compared with other aminoglycosides against isolates from european and adjacent countries, including enterobacteriaceae molecularly characterized for aminoglycoside-modifying enzymes and other resistance mechanisms. J Antimicrob Chemother. 2018;73(12):3346–3354.
   PubMed Web of Science ®Google Scholar
• Pragasam AK, Jennifer SL, Solaimalai D, et al. Expected plazomicin susceptibility in India based on the prevailing aminoglycoside resistance mechanisms in gram-negative organisms derived from whole-genome sequencing. Indian J Med Microbiol. 2020;38(3–4):313–318.
   PubMed Web of Science ®Google Scholar